ARTICLE | Finance

Paid in full

PDL BioPharma, Genentech wrangle over antibody royalties

September 6, 2010 7:00 AM UTC

Paid in full . . .

Two weeks after announcing it got a letter from Genentech Inc. that could put nearly a third of its royalty revenue at risk, PDL BioPharma Inc. (NASDAQ:PDLI) was happy to report last week that Genentech paid its 2Q bill in full. PDL also introduced 3Q10 revenue guidance of $86 million...